SCHEMBL7199549

SCHEMBL7199549

COc1ccc2c(c1)=COCC=2CO

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.33
KDM4E B2RXH2 3/20 0.33
MAPT P10636 3/20 0.33
MEN1 O00255 2/20 0.33
THRB P10828 2/20 0.33
KMT2A Q03164 2/20 0.33
GAA P10253 1/20 0.33
RECQL P46063 1/20 0.33
BLM P54132 1/20 0.33
MCL1 Q07820 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
ABCB11 O95342 1/20 0.33
ALOX5 P09917 1/20 0.32
HPGD P15428 3/20 0.32
CYP3A4 P08684 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C19 P33261 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7199002 0.85 MAOB (0.36) ALDH1A1KDM4EMAPTMEN1THRB
SCHEMBL7203576 0.81 NR5A1 (0.40) MEN1KMT2AGAAALOX5NPC1
SCHEMBL5225148 0.76 MTNR1A (0.52) MTNR1A
SCHEMBL26908653 0.69 CA12 (0.42) ALDH1A1KDM4EMAPTMEN1THRB
SCHEMBL5229799 0.64 CA12 (0.36) ALDH1A1KDM4EMAPTMEN1THRB
SCHEMBL2061056 0.59 KDM4E (0.50) ALDH1A1KDM4EHSD17B10CYP11B1CYP11B2
SCHEMBL346791 0.59 CA1 (0.56) ALDH1A1KDM4EMAPTMEN1THRB
SCHEMBL1134725 0.59 CA1 (0.56) ALDH1A1KDM4EMAPTMEN1THRB
SCHEMBL26768678 0.58 BAZ2B (0.56) ALDH1A1KDM4EMAPTMEN1KMT2A
Hydrochloric Acid SCHEMBL8068252 0.57 ADRA1A (0.47) ALDH1A1KDM4EMAPTMEN1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6602903-B2 Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. LES LABORATORIES SERVIER (FR) 2003-08-05 US disclosed
US-20020052400-A1 Substituted heterocyclic compounds ADIR ET COMPAGNIE 2002-05-02 US disclosed
US-6313160-B1 FOR THERAPY AND PROPHYLAXIS OF MELATONINERGIC DISORDERS ADIR ET COMPAGNIE (FR) 2001-11-06 US disclosed
EP-0998471-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME ADIR ET COMPAGNIE (FR) 2000-05-10 EP disclosed
WO-1998052935-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME ADIR ET COMPAGNIE (FR) 1998-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052400-A1 Substituted heterocyclic compounds MTNR1A, MTNR1B, CBR1 ALDH1A1 486/4885KDM4E 2431/4885MAPT 3970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.